April 7 (Reuters) - Imugene Ltd IMU.AX :
* IMUGENE- COHORT REVIEW COMMITTEE CONFIRMED PHASE I CLINICAL TRIAL OF PD1-VAXX, WILL PROCEED TO THIRD AND FINAL HIGHEST DOSE COHORT
April 7 (Reuters) - Imugene Ltd IMU.AX :
* IMUGENE- COHORT REVIEW COMMITTEE CONFIRMED PHASE I CLINICAL TRIAL OF PD1-VAXX, WILL PROCEED TO THIRD AND FINAL HIGHEST DOSE COHORT